MCID: BLD131
MIFTS: 55

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Urothelial Carcinoma

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 14
Transitional Cell Carcinoma of Bladder 12 69
Transitional Cell Carcinoma of the Bladder 28
Urinary Bladder Urothelial Carcinoma 12
Bladder Transitional Cell Carcinoma 12
Carcinoma Transitional Cell Bladder 51
Urothelial Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4006
NCIt 46 C39851
SNOMED-CT 64 255109008 393562002
UMLS 69 C0279680

Summaries for Bladder Urothelial Carcinoma

Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of bladder, is related to transitional cell carcinoma and inverted papilloma. An important gene associated with Bladder Urothelial Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include the lining of the bladder, kidney and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 32.5 CDH1 FGFR3 KRT20 KRT7 TP53 UPK3A
2 inverted papilloma 30.4 KRT20 KRT7 TP53
3 small cell carcinoma 30.4 KRT20 KRT7 TP53
4 papilloma 29.8 CCND1 FGFR3 KRT20 KRT7 RB1 TP53
5 adenocarcinoma 28.8 BRAF CCND1 CDH1 FGFR3 HRAS RB1
6 non-papillary transitional cell carcinoma of the bladder 12.4
7 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.2
8 clear cell variant infiltrating bladder urothelial carcinoma 12.2
9 non-invasive bladder urothelial carcinoma 12.2
10 micropapillary variant infiltrating bladder urothelial carcinoma 12.2
11 lipid-cell variant infiltrating bladder urothelial carcinoma 12.2
12 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.2
13 nested variant infiltrating bladder urothelial carcinoma 12.2
14 microcystic variant infiltrating bladder urothelial carcinoma 12.2
15 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.1
16 invasive bladder transitional cell carcinoma 11.3
17 cystic basal cell carcinoma 10.6 KRT20 KRT7
18 renal pelvis transitional cell carcinoma 10.6 KRT7 UPK3A
19 cerebral convexity meningioma 10.6 CDH1 TP53
20 lung acinar adenocarcinoma 10.6 KRT20 KRT7
21 pre-malignant neoplasm 10.6 CCND1 CDH1 TP53
22 bladder papillary transitional cell neoplasm 10.6 FGFR3 KRT20 TP53
23 urinary tract papillary transitional cell benign neoplasm 10.6 FGFR3 KRT20 TP53
24 vaginal benign neoplasm 10.6 KRT20 KRT7
25 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
26 transverse colon cancer 10.5 KRT20 KRT7
27 large intestine adenocarcinoma 10.5 CDH1 KRT20 KRT7
28 linitis plastica 10.5 CDH1 KRT20 KRT7
29 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
30 adenoid squamous cell carcinoma 10.5 CDH1 KRT20 KRT7
31 keratocystic odontogenic tumor 10.5 CCND1 FHIT TP53
32 gastric diffuse adenocarcinoma 10.5 CDH1 KRT20 KRT7
33 non-invasive bladder papillary urothelial neoplasm 10.5 FGFR3 TP53 UPK3A
34 tongue cancer 10.5 CCND1 CDH1 TP53
35 vaginal adenoma 10.5 KRT20 KRT7
36 eccrine sweat gland neoplasm 10.5 KRT20 KRT7 TP53
37 jejunal adenocarcinoma 10.5 CCND1 KRT20 KRT7
38 lymphoepithelioma-like carcinoma 10.5 CDH1 KRT20 KRT7
39 papillary serous adenocarcinoma 10.5 KRT20 KRT7 TP53
40 vaginal tubulovillous adenoma 10.5 KRT20 KRT7
41 infiltrative basal cell carcinoma 10.5 CDH1 KRT20 KRT7
42 glycogen-rich clear cell breast carcinoma 10.5 KRT20 KRT7 TP53
43 ductal carcinoma in situ 10.5 CCND1 CDH1 TP53
44 bartholin's duct cyst 10.5 GATA3 TP53
45 hidradenocarcinoma 10.5 CCND1 KRT7 TP53
46 endocervical adenocarcinoma 10.5 KRT20 KRT7 TP53
47 tongue squamous cell carcinoma 10.5 CASP3 CDH1 TP53
48 short-rib thoracic dysplasia 4 with or without polydactyly 10.5 CASP3 TP53
49 cervix carcinoma 10.5 FGFR3 FHIT TP53
50 malignant epithelial mesothelioma 10.5 CDH1 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 CASP3 DNMT3B LDHB RB1 TNFRSF6B TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BRAF CASP3 CCND1 DNMT3B LDHB RB1

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 AGGF1 CASP3 BRAF CCND1 FGFR3 CDH1
2 homeostasis/metabolism MP:0005376 10.34 CASP3 BRAF CCND1 FGFR3 CDH1 FHIT
3 cardiovascular system MP:0005385 10.33 AGGF1 CASP3 BRAF CCND1 CDH1 DNMT3B
4 mortality/aging MP:0010768 10.32 AGGF1 CASP3 BRAF CCND1 FGFR3 CDH1
5 immune system MP:0005387 10.29 CASP3 BRAF CCND1 FGFR3 CDH1 FHIT
6 hematopoietic system MP:0005397 10.28 CASP3 BRAF CCND1 FGFR3 FHIT DNMT3B
7 digestive/alimentary MP:0005381 10.27 BRAF CCND1 CASP3 FGFR3 CDH1 FHIT
8 endocrine/exocrine gland MP:0005379 10.26 CASP3 BRAF CCND1 CDH1 DNMT3B GATA3
9 craniofacial MP:0005382 10.23 BRAF CCND1 CASP3 FGFR3 DNMT3B GATA3
10 integument MP:0010771 10.19 CASP3 BRAF CCND1 FGFR3 CDH1 FHIT
11 nervous system MP:0003631 10.17 AGGF1 CASP3 BRAF CCND1 FGFR3 DNMT3B
12 neoplasm MP:0002006 10.16 AGGF1 BRAF CCND1 FGFR3 CDH1 DNMT3B
13 no phenotypic analysis MP:0003012 10.06 CASP3 FGFR3 CDH1 DNMT3B GATA3 RB1
14 hearing/vestibular/ear MP:0005377 10.02 CASP3 BRAF FGFR3 GATA3 RB1 TP53
15 renal/urinary system MP:0005367 9.97 CASP3 BRAF FGFR3 GATA3 RB1 HRAS
16 reproductive system MP:0005389 9.96 CASP3 BRAF CCND1 FGFR3 CDH1 DNMT3B
17 pigmentation MP:0001186 9.77 CASP3 BRAF GATA3 RB1 TP53
18 respiratory system MP:0005388 9.76 AGGF1 CASP3 BRAF CCND1 FGFR3 RB1
19 skeleton MP:0005390 9.7 CASP3 BRAF CCND1 FGFR3 DNMT3B GATA3
20 vision/eye MP:0005391 9.28 CASP3 BRAF CCND1 FGFR3 DNMT3B GATA3

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
4
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
5
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
6
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Vinblastine Approved Phase 3,Phase 2 865-21-4 241903 13342
12
Aminolevulinic acid Approved Phase 3 106-60-5 137
13
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
14
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
15
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
18
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
19 Tocopherol Approved, Investigational, Nutraceutical Phase 3
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
22
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
23
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
24
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
25
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
26
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
27
BCG vaccine Investigational Phase 3,Phase 2,Phase 1
28
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
29
Levulinic acid Experimental Phase 3 123-76-2 11579
30
Fenretinide Investigational Phase 3 65646-68-6
31 Anti-Infective Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Liposomal amphotericin B Phase 2, Phase 3
37 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
38 Antioxidants Phase 3
39 Micronutrients Phase 3,Phase 2,Early Phase 1
40 Protective Agents Phase 3
41 Tocopherols Phase 3
42 Tocotrienols Phase 3
43 Trace Elements Phase 3,Phase 2,Early Phase 1
44 Vitamins Phase 3,Phase 2
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
46 Antimitotic Agents Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
48 Vitamin B Complex Phase 3,Phase 2
49 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
50 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 190)

# Name Status NCT ID Phase Drugs
1 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
2 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
3 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
4 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
5 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
6 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
7 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
8 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
9 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
10 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
11 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
12 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
13 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
14 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
15 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
16 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
17 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
18 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
19 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
20 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
21 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
22 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
23 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
24 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
25 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
26 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
27 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
28 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
29 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
30 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
31 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
32 BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Terminated NCT00352079 Phase 3 gefitinib
33 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
34 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
35 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
36 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3 mitomycin C
37 Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
38 PF-03446962 in Relapsed or Refractory Urothelial Cancer Unknown status NCT01620970 Phase 2 PF03446962
39 Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder Unknown status NCT00694915 Phase 2
40 Alisertib in Chemotherapy-pretreated Urothelial Cancer Unknown status NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
41 Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
42 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
43 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
44 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
45 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
46 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
47 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
48 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder Completed NCT00963859 Phase 2
49 Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer Completed NCT01118351 Phase 2 sunitinib malate
50 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 28

Anatomical Context for Bladder Urothelial Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

18
The Lining Of The Bladder

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

38
Kidney, Prostate, Lung, Testes, Endothelial, Lymph Node, Liver

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 98)
# Title Authors Year
1
Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis. ( 29391889 )
2018
2
miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. ( 29379304 )
2018
3
Nkx2.8 inhibits epithelial-mesenchymal transition in bladder urothelial carcinoma via transcriptional repression of Twist1. ( 29311157 )
2018
4
Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. ( 29416608 )
2018
5
Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy. ( 29084921 )
2018
6
A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. ( 28060759 )
2017
7
The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway. ( 28548944 )
2017
8
Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. ( 28789622 )
2017
9
Ganoderma microsporum immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells. ( 29240252 )
2017
10
Vaginal metastasis of bladder urothelial carcinoma: Description of a case and revision of literature. ( 28679193 )
2017
11
High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma. ( 27959455 )
2017
12
Clinicopathological implications to micropapillary bladder urothelial carcinoma of the presence of sialyl Lewis X-decorated mucin 1 in stroma-facing membranes. ( 28666720 )
2017
13
Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/I^-catenin pathway. ( 29179467 )
2017
14
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy. ( 29061831 )
2017
15
Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma. ( 29179514 )
2017
16
Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. ( 28356754 )
2017
17
Mex3a expression and survival analysis of bladder urothelial carcinoma. ( 28903380 )
2017
18
Bladder urothelial carcinoma extending to rectal mucosa and presenting with rectal bleeding. ( 28690772 )
2017
19
Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-I_B/MMP-7 signaling pathway. ( 28333147 )
2017
20
Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. ( 28347658 )
2017
21
Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. ( 28600503 )
2017
22
The prognostic value of preoperative serum albumin-globulin ratio for high-grade bladder urothelial carcinoma treated with radical cystectomy: A propensity score-matched analysis. ( 29237914 )
2017
23
Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma. ( 28488128 )
2017
24
Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma. ( 29151933 )
2017
25
Laparoendoscopic Single-Site Radical Cystectomy vs Conventional Laparoscopic Radical Cystectomy for Patient with Bladder Urothelial Carcinoma: Matched Case-Control Analysis. ( 28967303 )
2017
26
Expression of AR, 5I+R1 and 5I+R2 in bladder urothelial carcinoma and relationship to clinicopathological factors. ( 28947209 )
2017
27
Identification and functional analysis of risk-related microRNAs for the prognosis of patients with bladder urothelial carcinoma. ( 29344166 )
2017
28
Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. ( 28396613 )
2017
29
Contrast-Enhanced Ultrasound Differentiation Between Low- and High- Grade Bladder Urothelial Carcinoma and Correlation With Tumor Microvessel Density. ( 28556470 )
2017
30
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. ( 28291636 )
2017
31
Independent prognostic miRNAs for bladder urothelial carcinoma. ( 28928837 )
2017
32
Transmembrane and Coiled-Coil Domain 1 Impairs the AKT Signaling Pathway in Urinary Bladder Urothelial Carcinoma: A Characterization of a Tumor Suppressor. ( 28972042 )
2017
33
LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. ( 28969069 )
2017
34
Female, Black, and Unmarried Patients Are More Likely to Present With Metastatic Bladder Urothelial Carcinoma. ( 27212042 )
2016
35
Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. ( 27181205 )
2016
36
Clarification of the molecular pathway of Taiwan local pomegranate fruit juice underlying the inhibition of urinary bladder urothelial carcinoma cell by proteomics strategy. ( 26955879 )
2016
37
Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience. ( 27563483 )
2016
38
Retrospective study of various conservative treatment options with bacille Calmette-GuAcrin in bladder urothelial carcinoma T1G3: Maintenance therapy. ( 26922518 )
2016
39
Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma. ( 26852969 )
2016
40
The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. ( 27341738 )
2016
41
Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma. ( 27599849 )
2016
42
Differential effects of adipose tissue stromal cells on the apoptosis, growth and invasion of bladder urothelial carcinoma between the superficial and invasive types. ( 27020040 )
2016
43
Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance. ( 27752905 )
2016
44
A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. ( 26812572 )
2016
45
Evaluation of the role of immunohistochemical expression of EGFR (ERB B1) and HER4 (ERB B4) in urinary bladder urothelial carcinoma. ( 27772841 )
2016
46
Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. ( 27505309 )
2016
47
Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway. ( 27440446 )
2016
48
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. ( 26869805 )
2016
49
T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. ( 26265374 )
2015
50
E-cadherinA^CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas. ( 25826491 )
2015

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 94)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
4 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
13 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
15 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
16 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
24 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
25 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
26 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
27 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
28 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
29 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
30 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
31 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
32 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
33 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
34 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
35 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
36 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
37 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
38 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
39 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
40 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
41 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
42 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
43 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
44 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
45 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
46 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
47 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
48 MAP2K1 NM_002755.3(MAP2K1): c.371C> T (p.Pro124Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397516792 GRCh37 Chromosome 15, 66729163: 66729163
49 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
50 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155

Cosmic variations for Bladder Urothelial Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 18

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 BRAF CASP3 CCND1 CDH1 FGFR3 HRAS
2
Show member pathways
13.3 BRAF CASP3 CCND1 FGFR3 GATA3 HRAS
3
Show member pathways
12.96 CASP3 CCND1 FGFR3 HRAS RB1 TP53
4
Show member pathways
12.87 CASP3 HRAS RB1 TNFRSF6B TP53
5
Show member pathways
12.79 BRAF CASP3 CCND1 CDH1 FGFR3 FHIT
6 12.74 BRAF CASP3 FGFR3 HRAS TP53
7
Show member pathways
12.7 BRAF CASP3 CDH1 HRAS TP53
8
Show member pathways
12.69 BRAF CCND1 CDH1 HRAS RB1 TP53
9 12.65 BRAF CASP3 CCND1 CDH1 FGFR3 HRAS
10
Show member pathways
12.63 BRAF CASP3 HRAS RB1 TP53
11
Show member pathways
12.52 BRAF CCND1 HRAS RB1 TP53
12
Show member pathways
12.51 CASP3 CCND1 HRAS RB1 TP53
13
Show member pathways
12.42 BRAF CASP3 CDH1 HRAS TP53
14 12.41 CCND1 HRAS RB1 TP53
15
Show member pathways
12.39 CASP3 FGFR3 HRAS TGFBR3 TP53
16 12.39 CASP3 CCND1 DNMT3B FGFR3 HRAS TP53
17
Show member pathways
12.38 CCND1 GATA3 HRAS TP53
18
Show member pathways
12.34 CASP3 CCND1 RB1 TP53
19 12.34 CCND1 CDH1 RB1 TP53
20
Show member pathways
12.25 BRAF CASP3 HRAS TP53
21
Show member pathways
12.25 CASP3 RB1 SATB1 TNFRSF6B
22
Show member pathways
12.24 CASP3 CCND1 RB1 TP53
23 12.22 BRAF CASP3 CCND1 HRAS TP53
24 12.2 CASP3 CCND1 HRAS RB1 TP53
25
Show member pathways
12.14 BRAF HRAS TGFBR3 TP53
26 12.13 CCND1 HRAS RB1 TP53
27
Show member pathways
12.09 BRAF CASP3 HRAS TP53
28 12.09 BRAF CASP3 CCND1 CDH1 TP53
29
Show member pathways
12.04 BRAF CCND1 HRAS RB1 TP53
30 11.96 CASP3 CCND1 RB1 TP53
31 11.88 BRAF HRAS RB1 TP53
32
Show member pathways
11.88 BRAF CASP3 CCND1 FGFR3 HRAS RB1
33 11.85 BRAF CCND1 HRAS RB1 TP53
34 11.82 CCND1 RB1 TP53
35
Show member pathways
11.79 BRAF CASP3 HRAS
36 11.73 CASP3 CCND1 FHIT RB1 TP53
37 11.68 BRAF HRAS RB1
38 11.65 FGFR3 HRAS TP53
39 11.62 BRAF CASP3 CCND1 CDH1 RB1 TP53
40 11.56 CASP3 CCND1 TP53
41
Show member pathways
11.54 DNMT3B HRAS RB1
42 11.53 CASP3 CCND1 TP53
43 11.53 CCND1 RB1 TP53
44 11.46 CASP3 RB1 TP53
45 11.39 BRAF FGFR3 HRAS
46 11.09 BRAF CCND1 CDH1 FGFR3 HRAS RB1
47 11.06 CCND1 HRAS RB1

GO Terms for Bladder Urothelial Carcinoma

Cellular components related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 AGGF1 BRAF CASP3 CCND1 CDH1 DNMT3B

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 CCND1 DNMT3B GATA3 RB1 SATB1 TP53
2 positive regulation of gene expression GO:0010628 9.8 BRAF DNMT3B GATA3 HRAS TP53
3 response to organic substance GO:0010033 9.7 CASP3 CCND1 CDH1
4 chromatin remodeling GO:0006338 9.69 GATA3 RB1 SATB1
5 Ras protein signal transduction GO:0007265 9.63 HRAS RB1 TP53
6 negative regulation of cell cycle GO:0045786 9.5 CASP3 GATA3 RB1
7 response to caffeine GO:0031000 9.49 DNMT3B TP53
8 mitotic G1 DNA damage checkpoint GO:0031571 9.48 CCND1 TP53
9 response to drug GO:0042493 9.43 CASP3 CCND1 CDH1 DNMT3B GATA3 TP53
10 CD4-positive, alpha-beta T cell differentiation GO:0043367 9.37 BRAF SATB1
11 response to X-ray GO:0010165 9.33 CASP3 CCND1 TP53
12 glial cell apoptotic process GO:0034349 9.26 CASP3 RB1
13 apoptotic process GO:0006915 9.23 CASP3 FGFR3 FHIT HRAS KRT20 RB1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 AGGF1 BRAF CASP3 CCND1 CDH1 DNMT3B
2 identical protein binding GO:0042802 9.5 BRAF CDH1 FGFR3 FHIT LDHB RB1

Sources for Bladder Urothelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....